Quality Of Life in Patients With Malignant Biliary Obstruction
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00579865|
Recruitment Status : Completed
First Posted : December 24, 2007
Last Update Posted : January 14, 2010
|Condition or disease||Intervention/treatment|
|Gallbladder Cancer Liver Cancer Bile Duct Cancer||Behavioral: questionnaires|
|Study Type :||Observational|
|Actual Enrollment :||124 participants|
|Official Title:||Impact of Biliary Drainage on Quality Of Life in Patients With Malignant Biliary Obstruction|
|Study Start Date :||May 2005|
|Primary Completion Date :||January 2010|
|Study Completion Date :||January 2010|
Patients scheduled for percutaneous drainage
complete the FACT-Hep, the SSQ, and the Visual Analog Scale for Pruritus Assessment at 1 week and 4 weeks post procedure.
Patients scheduled for a surgical bypass or resection of a high bile duct tumor.
complete the FACT-Hep, the SSQ, and the Visual Analog Scale for Pruritus Assessment at 1 week and 4 weeks post procedure. Patients who have undergone bypass or resection will complete an additional set of questionnaires at 9 and 14 weeks.
- To determine how surgical or percutaneous drainage affects HRQL scores in patients with MBO, and to determine if these changes are sustained or change over time. [ Time Frame: conclusion of the study ]
- To identify factors associated with changes in HRQL after drainage(e.g. diagnosis, level of obstruction, degree of pruritus) [ Time Frame: conclusion of the study ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00579865
|United States, New York|
|Memorial Sloan Kettering Cancer Center|
|New York, New York, United States, 10065|
|Principal Investigator:||Piera Robson, RN, BSN||Memorial Sloan Kettering Cancer Center|